PATHFINDER 2 Study

This is a prospective, multi-center interventional study of GRAIL’s multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of GRAIL’s MCED test in a population of individuals aged 50 years and older who are not actively being evaluated or treated for cancer. Participants with a “cancer signal detected” test result will receive targeted diagnostic procedures based on the predicted cancer signal origin(s) to determine if cancer is present. The number and types of diagnostic procedures needed to achieve diagnostic resolution will be assessed. Participant-reported outcomes will be collected at several time points to assess perceptions about the multi-cancer early detection test, as well as use of guideline-recommended standard of care cancer screening tests.

The study will enroll approximately 35,000 eligible participants over an anticipated enrollment period of approximately 36 months. Participants will be actively followed for approximately 3 years.

Current Status:
Collaborators
Cleveland clinic logo
Eastern Virginia Medical School
Flushing Hospital Medical Center
henry ford health system logo
Inova Health System logo
Jamaica Hospital Medical Center
kelsey seybold clinic
Mayo Clinic Logo
MedStar Washington Hospital Center
memorial care
Morehouse School of Medicine
Palo Alto Medical Foundation
sarah cannon logo
sutter health logo
University of Oklahoma
The US Oncology LOGO
University of Illinois
Weill Cornell Medicine